ArticleOpen veterinary journal2024
Molecular docking of eleven snake venom peptides targeting human immunodeficiency virus capsid glycoprotein as inhibitors.
Article in Open veterinary journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computational modeling approach to identify potential anti-Campylobacter peptides fromOpen veterinary journal · 2025Review
- Neuraminidase as a novel therapeutic management strategy for Alzheimer's disease: evidenced through molecular docking, molecular dynamic simulation and gene expression analysis.Frontiers in chemistry · 2025Article
- Exploring the SARS-CoV-2 spike protein destabilizer toxin from the scorpion, spider, and wasp group of toxins as a promising candidate for the identification of pharmacophores against viral infections.Open veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Snake venoms are mainly composed of a mixture of proteins and peptides with antiviral activity against several viruses including HIV. Therefore, snake venoms represent a promising source for new antiviral drugs. Aim: The study examines the toxin's capacity to disrupt the spike glycoprotein of HIV, the virus accountable for the HIV epidemic. Methods: The active protein structure of HIV and snake toxins was derived from the protein RCSB-PDB. The interactions between this toxin and the spike protein were evaluated using molecular docking software/interface such as " Results: The latest study findings uncover fascinating affinities and interaction patterns between snake poisons and the HIV spike glycoprotein. We analyzed the consequences of these interactions and their capacity to impair viral entry and infection. Conclusion: This work highlights a prospective approach for the advancement of antiviral treatments, utilizing nature's collection of toxins as a basis for pharmacophore-based medication exploration against viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.